KRRO
Korro Bio, Inc.
$12.28
-0.75 (-5.76%)
At close · Jul 16
Market Cap
$177.11M
Shares
14,422,571
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$6.39M
+181.5%
FY2025
Net Income
-$117.26M
-40.3%
FY2025
Operating Margin
-1906.37%
+2140.8pp
FY2025
Diluted EPS
-$12.48
-33.2%
FY2025
Operating Cash Flow
-$78.56M
-30.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $3.84M | $6.39M | $2.27M | $0 | $0 | $14.07M | $36.98M | $28.95M | — | — | |
| — | — | — | $0 | -$118K | — | — | $1.78M | -$106K | -$174K | |
| $58.79M | $65.58M | $63.64M | $57.25M | $42.2M | $60.92M | $37.42M | $18.78M | $11.88M | $11.97M | |
| $27.81M | $28.16M | $30.55M | $27.28M | $16.8M | $37.18M | $27.12M | $14.84M | $7.06M | $4.34M | |
| — | $3.63M | $0 | — | — | — | — | — | — | — | |
| $121.11M | $128.25M | $94.18M | $84.53M | $59M | $98.1M | $64.53M | $49.62M | $18.94M | $16.31M | |
| -$117.27M | -$121.86M | -$91.91M | -$84.53M | -$59M | -$84.03M | -$27.55M | -$20.68M | -$18.94M | -$16.31M | |
| — | -1906.37% | -4047.12% | — | — | -597.32% | -74.49% | -71.42% | — | — | |
| $596K | — | — | — | $961K | $764K | $0 | — | — | — | |
| $1.77M | — | — | — | $1.33M | $397K | $994K | $1.78M | — | — | |
| $4.51M | $5.23M | $8.47M | $3.39M | $976K | -$266K | — | — | — | — | |
| — | — | — | — | — | -$84.67M | -$26.48M | — | — | — | |
| -$112.77M | -$116.62M | -$83.44M | -$81.15M | -$58.02M | -$84.67M | -$26.48M | -$18.75M | — | — | |
| $732K | $637K | $141K | $27K | $10K | $15K | $35K | $0 | — | — | |
| -$113.5M | -$117.26M | -$83.58M | -$81.17M | -$58.03M | -$84.69M | -$26.51M | -$18.75M | -$19.17M | -$20.24M | |
| — | -1834.48% | -3680.36% | — | — | -601.98% | -71.68% | -64.76% | — | — | |
| — | — | — | — | — | -$84.69M | -$26.51M | -$19.8M | -$19.17M | -$20.24M | |
| -$113.76M | -$117.32M | -$83.31M | -$81.17M | -$58.03M | -$84.78M | -$26.54M | -$18.69M | -$19.17M | -$20.24M | |
| USD/shares | — | -$12.48 | -$9.37 | -$53.08 | -$227.42 | — | — | — | — | — |
| USD/shares | — | -$12.48 | -$9.37 | -$53.08 | -$227.42 | — | — | — | — | — |
| shares | — | 9.4M | 8.92M | 1.53M | 255.18K | 687.03K | 645.06K | 172.98K | 30.6K | 14.06K |
| shares | — | 9.4M | 8.92M | 1.53M | 255.18K | 687.03K | 645.06K | 172.98K | 30.6K | 14.06K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 7.92×
EV/EBIT
—
Biotechnology median 26.64×
P/E (TTM)
—
Biotechnology median 7.53×